EGFR and non-small cell lung carcinoma: Although comprehensive genetic analyses of EC have been conducted, driver gene mutations, such as EGFR mutations in non-small cell lung cancer, are yet to be identified, and cytotoxic anticancer drugs remain the key drugs.